SARS-CoV-2 Omicron BA.1 Variant Pseudovirus | 95-201

SARS-CoV-2 Omicron BA.1 Variant Pseudovirus | 95-201 | Gentaur UK, US & Europe Distribution

Product Type: Pseudovirus

Category: New/Featured Products

Research Area: Infectious Disease, COVID-19

Tested Applications: Neut, Viral Infection

Protocol:

1. Require BSL-2 or higher working environment
2. 5 μL per application (96-well plate) with at least 0.3 X 10⁶ RLU / well.
3. Avoid freezing and thawing cycle to ensure the titer of the pseudovirus.
4. This product is for Research Use only
5. Neutralization assay protocol is available

Physical State: Liquid

Buffer: DMEM/10% FBS

Storage: The pseudovirus is stable in a liquid state at -70˚ for 12 months. Avoid repeated freeze-thaw cycles.

Additional Names:

Physical State: Liquid

Buffer: DMEM/10% FBS

Storage: The pseudovirus is stable in a liquid state at -70˚ for 12 months. Avoid repeated freeze-thaw cycles.

Additional Names: Spike glycoprotein Receptor-binding domain, S glycoprotein, Spike protein, Omicron variant spike, Omicron variant pseudovirus, Omicron, pseudovirus reporter, reporter virus particle 

Protein Accession: QHD43416

Protein GI Number: 1791269090

NCBI Gene ID: 43740568

Background: SARS-CoV-2 Pseudovirus uses HIV pseudotyped with SARS-CoV-2 spike protein and firefly luciferase reporter. This pseudovirus effectively infects human ACE2-overexpressing cells and can be used to screen for inhibitors of Spike-ACE2 interaction, determine neutralizing antibody titers, and is a valuable tool for COVID-19 vaccine development as well.

Protein Accession: QHD43416

Protein GI Number: 1791269090

NCBI Gene ID: 43740568

Background: SARS-CoV-2 Pseudovirus uses HIV pseudotyped with SARS-CoV-2 spike protein and firefly luciferase reporter. This pseudovirus effectively infects human ACE2-overexpressing cells and can be used to screen for inhibitors of Spike-ACE2 interaction, determine neutralizing antibody titers, and is a valuable tool for COVID-19 vaccine development as well.